SAMDaily.us | MOD | 66 | JEOL USA, Inc., JNM-ECZL400S NMR Spectrometer system with Royal HFX NMR Probe, accessories, shipping, and installation or equal (COVID-19 action)

SAMDAILY.US - ISSUE OF MAY 22, 2022 SAM #7478
MODIFICATION

66 -- JEOL USA, Inc., JNM-ECZL400S NMR Spectrometer system with Royal HFX NMR Probe, accessories, shipping, and installation or equal (COVID-19 action)

Notice Date: 5/20/2022 12:30:53 PM
Notice Type: Combined Synopsis/Solicitation
NAICS: 334516 — Analytical Laboratory Instrument Manufacturing
Contracting Office: NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
ZIP Code: 20892
Solicitation Number: 75N95022Q00260
Response Due: 5/30/2022 6:00:00 AM
Archive Date: 06/14/2022
Point of Contact: Renato Gomes
E-Mail Address: renato.gomes@nih.gov
(renato.gomes@nih.gov)
Description: �(i)�� This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii)�� The solicitation number is 75N95022Q00260 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13�Simplified Acquisition Procedures; FAR Subpart 13.5� Simplified Procedures for Certain Commercial Items; and FAR Part 12�Acquisition of Commercial Items, and is expected to exceed the simplified acquisition threshold. (iii)�� The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2022-06, with effective date 05/01/2022. (iv)�� The associated NAICS code is 334516 - Analytical Laboratory Instrument Manufacturing and the small business size standard is 1000 employees. This requirement is full and open with no set-aside restrictions. (v)�� The National Institutes of Health (NIH) is the nation�s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting, and making medical discoveries that improve people�s health and save lives. NCATS is one of 27 Institutes and Centers at the NIH, and its mission is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. The NCATS DPI plans, conducts, and uses both internal and contract resources to advance collaborative research projects across the preclinical phases of the translational science spectrum. The NCATS DPI Analytical Chemistry Core (ACC) maintains a state-of-the-art laboratory whose mission is to support translational research throughout NCATS by providing analytical chemistry services involving the isolation, purification, identification, and analysis of various therapeutic modalities for targeted disease states. Moreover, NCATS has become a key partner in the Antiviral Program for Pandemics (APP), a multi-agency initiative that includes National Institute of Allergy and Infectious Diseases (NIAID) and Biomedical Advanced Research and Development Authority (BARDA), to accelerate antiviral development through early discovery and preclinical development of safe and effective oral antivirals. The initial priority for the APP is to develop treatments for SARS-CoV-2 and other coronaviruses, with the program expanding to address other virus families with pandemic potential. NCATS will apply its proficiency in drug discovery and development and its cutting-edge technologies to fill critical needs of the APP, such as (i) target validation, (ii) high-throughput screening (HTS) for drug starting points, (iii) medicinal chemistry for lead optimization, and (iv) preclinical, investigational new drug (IND)-enabling development. Nuclear magnetic resonance (NMR) spectroscopy is arguably the most powerful analytical tool a chemist has at their disposal for the identification and confirmation of organic molecules. Medicinal chemists at DPI use the NMR instruments daily to collect compound data, as well as conduct more advanced NMR experiments overnight. Constant access to fully functioning NMR instruments is imperative to maintain productivity in the successful pursuit of the DPI mission. Moreover, with chemical and pharmaceutical technologies continuing to evolve, NMR systems have improved and evolved to meet their needs. It is crucial that the medicinal chemists at DPI have access to the latest NMR technologies to streamline and simplify their analytical chemistry workflows. In this case, one of the ACC's NMR systems (NMR2) is approaching 15 years old, has components that are beginning to show substantial ware, and, consequently, is near end-of-life. As such, the ACC seeks to replace NMR2 with a new NMR Spectrometer capable of simultaneously tuning to both fluorine (19F) and proton (1H) in a single high-frequency channel, effectively creating a three-channel NMR system with no additional hardware�this increases ACC�s NMR capabilities without increasing the total cost of the NMR system. Moreover, the NMR software shall integrate with the CRAFT (Complete Reduction to Amplitude-Frequency Table) data processing on top of the standard NMR operating and data processing procedures. CRAFT is a tool that automatically and efficiently performs quantitative and statistical analyses in NMR systems. Thus, without acquisition of the JEOL USA, Inc., JNM-ECZL400S NMR Spectrometer system with Royal HFX NMR Probe, accessories, shipping, and installation (Brand-name or equal), the ACC will be unable to advance NCATS capabilities aimed at meeting the support and resource needs of the APP and DPI (vi)�� The Analytical Chemistry Core (ACC), within the Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) seeks to purchase a JEOL USA, Inc., JNM-ECZL400S NMR Spectrometer system with Royal HFX NMR Probe, accessories, shipping and installation or equal in order to advance NCATS identification and confirmation of organic molecules capabilities aimed at meeting the support and resource needs of the Antiviral Program for Pandemics (APP) and DPI. �� For reference purposes, the 400 MHz NMR spectrometer that meets the need of this requirement is the JEOL USA, Inc., JNM-ECZL400S NMR system with Royal HFX NMR Probe, accessories, shipping, and installation or Equal, as per the specific requirement and salient characteristics provided in the attached PURCHASE DESCRIPTION (PD). (vii)�� The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated delivery date is required within six (6) months after receipt of order (ARO). Delivery will be f.o.b. destination. The place of delivery and acceptance will be National Center for Advancing Translational Sciences (NCATS) at 9800 Medical Center Drive, Rockville, MD 20850. (viii)�� The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses:� https://www.acquisition.gov/browse/index/far�� https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html�� (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Oct 2018) FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) FAR 52.211-6, Brand Name or Equal (Aug 1999) FAR 52.212-1, Instructions to Offerors-Commercial Items (Nov 2021) FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Nov 2021) FAR 52.225-6, Trade Agreements Certificate (Feb 2021) FAR 52.229-11 Tax on Certain Foreign Procurements�Notice and Representation. (Jun 2020) HHSAR 352.239-73, Electronic and Information Technology Accessibility Notice (December 18, 2015) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far�� https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html� (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) FAR 52.212-4, Contract Terms and Conditions--Commercial Items (Nov 2021). Addendum to this FAR clause applies to this acquisition and is attached. HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) HHSAR 352.239-74, Electronic and Information Technology Accessibility (December 18, 2015) The following provisions and clauses apply to this acquisition and are attached in full text.� Offerors MUST complete the provisions at 52.204-24 and 52.204-26 and submit completed copies as separate documents with their proposal. FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders--Commercial Items (May 2022) NIH Invoice Instructions with IPP (April 2022) NIH Invoice Instructions without IPP (April 2022) (ix)�� The Government will evaluate quotations or offers in accordance with FAR 13.106-2 and award a purchase order from this solicitation to the responsible offeror whose quote conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate quotes: a. Technical capability of the item offered to meet the Government requirement; b. Price; and c. Past performance [see FAR 13.106-2(b)(3)]. � (x)�� The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items (Nov 2021), with its offer. If the offeror has completed FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer. (xi)�� The clause at FAR 52.212-4, Contract Terms and Conditions-Commercial Items (Nov 2021), applies to this acquisition. Addendum to this FAR clause applies to this acquisition and is attached. (xii)�� Additional contract requirement(s) or terms and conditions applicable to this acquisition: �� This COVID-19 requirement will be funded with COVID-19 funds at time of award. The following language is applicable and shall be included in the resultant COVID-19 award.� �HHS reserves the right to exercise priorities and allocations authority with respect to this contract, to include rating this order in accordance with 45 CFR Part 101, Subpart A� Health Resources Priorities and Allocations System.� (xiii)�� The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xiv)�� Responses to this solicitation must include sufficient information to establish the interested parties� bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s), product description, and any other information or factors that may be considered in the award decision. Such factors may include: past performance, special features required for effective program performance, trade-in considerations, probable life of the item selected as compared with that of a comparable item, warranty considerations, maintenance availability, and environmental and energy efficiency considerations. Respondents proposing on an equal product of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order.� The Unique Entity ID from SAM.gov, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All questions must be received by 9:00 a.m., Eastern Daylight/Standard Time, on May 24, 2022, and reference Solicitation Number 75N95022Q00260. Questions may be submitted electronically to Renato Gomes, Contract Specialist, at renato.gomes@nih.gov. All quotations must be received by 9:00 a.m., Eastern Daylight/Standard Time, on May 30, 2022, and reference Solicitation Number 75N95022Q00260. Responses must be submitted electronically to Renato Gomes, Contract Specialist, at renato.gomes@nih.gov. Fax responses will not be accepted. Attachments: Purchase Description FAR 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) FAR 52.204-26, Covered Telecommunications Equipment or Services-Representation(Oct 2020) Addendum to FAR 52.212-4 Terms and Conditions � Commercial Items FAR 52.212-5, Contract Terms and Conditions�Commercial Products and Commercial Services (May 2022) FAR 52.225-6, Trade Agreements Certificate (Feb 2021) FAR 52.229-11 Tax on Certain Foreign Procurements�Notice and Representation. (Jun 2020) NIH Invoice Instructions with IPP (April 2022) NIH Invoice Instructions without IPP (April 2022)
Web Link: SAM.gov Permalink
(https://sam.gov/opp/9eda4f07182747ca98ca626ea462670d/view)
Place of Performance: Address: Bethesda, MD 20892, USA; Zip Code: 20892; Country: USA
Record: SN06333627-F 20220522/220521211344 (samdaily.us)
Source: SAM.gov Link to This Notice
(may not be valid after Archive Date)

| FSG Index | This Issue's Index | Today's SAM Daily Index Page |

Loren Data's SAM Daily™

66 -- JEOL USA, Inc., JNM-ECZL400S NMR Spectrometer system with Royal HFX NMR Probe, accessories, shipping, and installation or equal (COVID-19 action)